Sugi Predict

Sugi Predict / Compounds / SCHEMBL14645313

SCHEMBL14645313

SCHEMBL14645313

O=C(O)Cc1ccsc1-c1ccc(-c2sccc2CC(=O)O)s1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.45
▸ TP53 P04637 1/20 0.45
▸ ALOX15 P16050 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ AKR1B1 P15121 2/20 0.38
▸ ALDH1A1 P00352 3/20 0.36
▸ MEN1 O00255 3/20 0.36
▸ USP2 O75604 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ KEAP1 Q14145 1/20 0.35
▸ NFE2L2 Q16236 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ PPARG P37231 1/20 0.34
▸ NCOA2 Q15596 1/20 0.34
▸ NCOA1 Q15788 1/20 0.34
▸ RXFP1 Q9HBX9 1/20 0.34
▸ PTGDR2 Q9Y5Y4 2/20 0.33
▸ GABRP O00591 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15695243 0.91 KMT2A (0.39) KMT2ATP53ALOX15MAPK1AKR1B1
SCHEMBL14646174 0.91 KMT2A (0.39) KMT2ATP53ALOX15MAPK1AKR1B1
SCHEMBL14646183 0.89 KMT2A (0.38) KMT2ATP53ALOX15MAPK1AKR1B1
SCHEMBL14646212 0.89 KMT2A (0.38) KMT2ATP53ALOX15MAPK1AKR1B1
SCHEMBL14646211 0.87 KMT2A (0.40) KMT2ATP53ALOX15MAPK1AKR1B1
SCHEMBL14646210 0.85 RPS6KB2 (0.44) KMT2ATP53ALOX15MAPK1AKR1B1
SCHEMBL14773950 0.84 KMT2A (0.35) KMT2ATP53ALOX15MAPK1AKR1B1
SCHEMBL14646178 0.83 ALDH1A1 (0.40) KMT2ATP53ALOX15MAPK1ALDH1A1
SCHEMBL14646184 0.83 KMT2A (0.43) KMT2ATP53ALOX15MAPK1ALDH1A1
SCHEMBL5053028 0.82 ALDH1A1 (0.47) KMT2ATP53ALOX15MAPK1AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9359311-B2 Substituted aromatic oligomers NEUROSCIOS GMBH (AT) 2016-06-07 — — US disclosed
US-9359311-B2 Substituted aromatic oligomers NEUROSCIOS GMBH (AT) 2016-06-07 — — US disclosed
EP-2817304-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BioChromix NewCo AB (SE) 2014-12-31 — — EP disclosed
US-20140135322-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BIOCHROMIX PHARMA AB 2014-05-15 — — US disclosed
US-20140135322-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BIOCHROMIX PHARMA AB 2014-05-15 — — US disclosed
WO-2013036196-A1 NOVEL THIOPHENE COMPOUNDS AND METHOD FOR IN VIVO IMAGING BIOCHROMIX AB (SE) 2013-03-14 — — WO disclosed
WO-2013036196-A1 NOVEL THIOPHENE COMPOUNDS AND METHOD FOR IN VIVO IMAGING BIOCHROMIX AB (SE) 2013-03-14 — — WO disclosed
WO-2013009259-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BIOCHROMIX PHARMA AB (SE) 2013-01-17 — — WO disclosed
WO-2013009259-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BIOCHROMIX PHARMA AB (SE) 2013-01-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140135322-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY PRNP, TBCA, HSPA5 KMT2A 4329/4885TP53 165/4885ALOX15 3805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.